论文部分内容阅读
近几年,全球的抗丙肝药物研究正以前所未有的速度发展。索菲布韦(Sovaldi)及其复方的出世改变了传统的治疗手段,索菲布韦12周疗程治愈率达90%以上,而传统标准方案聚乙二醇干扰素联合利巴韦林仅为44%~77%,不包括其不良反应和较长的用药周期。索菲布韦一经上市就达到110亿美元的年销售,同时160亿的巨大丙肝治疗药物市场。目前,先后已有多个抗丙肝药物上市与吉利德
In recent years, the global anti-hepatitis C drug research is growing at an unprecedented rate. The birth of Sovaldi and its companion changed the traditional treatment, Sophoclycin treatment over 12 weeks of treatment rate of 90%, while the traditional standard program of pegylated interferon combined with ribavirin only 44% ~ 77%, does not include its adverse reactions and longer medication cycles. Sophocles, once listed, has achieved annual sales of 11 billion U.S. dollars, while the huge 16 billion hepatitis C therapeutic drug market. At present, there have been multiple anti-hepatitis C drugs listed and Gilead